Zynrelef (bupivacaine;meloxicam)
- Region
- 🇪🇺 EU
- Active substance
- bupivacaine;meloxicam
- Company
- Heron Therapeutics, B.V.
- Status
- Withdrawn
- Therapeutic area
- Pain, Postoperative
- CHMP opinion
- Thu 23 Jul 2020
- EU approval
- Thu 24 Sep 2020
- Application
- EMEA/H/C/005205
- ATC
- N01B
- Official record
- www.ema.europa.eu
Indication
Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Follow Zynrelef
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.